INTRODUCTION

It is well documented that the higher the baseline HbA$_{1c}$, the greater the decline in HbA$_{1c}$ when oral antidiabetes agents are given to patients with type 2 diabetes.\textsuperscript{1-4} In patients with type 2 diabetes treated with an oral antidiabetes agent for ≥12 weeks, a 0.2%-0.5% greater decrement in HbA$_{1c}$ has been reported for every 1% higher baseline HbA$_{1c}$.\textsuperscript{1} In a meta-regression analysis of randomized controlled trials, treatment with dipeptidyl peptidase-4 (DPP4) inhibitors for ≥12 weeks led to a ≥0.26% greater reduction in HbA$_{1c}$ for every percentage point of baseline HbA$_{1c}$ >7%.\textsuperscript{2} The universality of these findings suggests a nonspecific mechanism. This mechanism
has yet to be determined, and could be related to on-treatment improvements in beta-cell or alpha-cell functions.5,6

Sodium-glucose cotransporter 2 (SGLT2) inhibitors inhibit sodium-glucose cotransport in the proximal tubule. This reduces the blood glucose level at which the capacity for glucose transport by SGLTs is saturated, and therefore, the blood glucose level at which glucose is spilled into the urine—also referred to as the renal threshold for glucose.7 By lowering the renal threshold for glucose, glucose that would otherwise be reabsorbed in the kidney is excreted into the urine. The constitutive renal threshold for plasma glucose in patients with type 2 diabetes is typically in the range of ~10-11 mmol/L (180-200 mg/dL) without SGLT2 inhibitor treatment.8 The amount of filtered glucose in the kidney is dependent on glomerular filtration rate (GFR) and blood glucose. Therefore, the amount of reabsorbed glucose increases linearly with blood glucose (for a given GFR) until the renal threshold for glucose is reached; with higher glucose levels, the reabsorbed glucose stays constant except for a minor splay between the two parts of the absorption curve.9,10 Glucose lowering with SGLT2 inhibitors is expected to increase linearly with increasing blood glucose up to approximately 10-11 mmol/L (representing the renal threshold for glucose in the untreated situation). This effect of SGLT2 inhibitors could differ from, and could possibly be in addition to, a nonspecific increase in glucose lowering with increasing blood glucose common to any glucose-lowering intervention. No study has compared the slope of the decrement in HbA1c in relation to baseline HbA1c with an SGLT2 inhibitor vs other oral antidiabetes agents. Empagliflozin is a potent and selective inhibitor of SGLT2.11 In Phase III trials in patients with type 2 diabetes, empagliflozin 10 mg/d and 25 mg/d as monotherapy or as add-on therapy significantly reduced HbA1c compared with placebo after 24 weeks of treatment.12-15 The reduction in HbA1c with empagliflozin monotherapy was significantly greater in patients with baseline HbA1c ≥8.5% compared with patients with baseline HbA1c <8.5%.12 We hypothesized that with increasing baseline HbA1c up to ~11% (ie, with a large proportion of blood glucose below the untreated renal threshold for glucose), empagliflozin would produce a greater HbA1c reduction in patients with type 2 diabetes compared with antidiabetes agents with other mechanisms of action. To test this hypothesis, we compared the slopes of regression in HbA1c with empagliflozin vs with sitagliptin or glimepiride using data from two randomized controlled trials in patients with type 2 diabetes. A major advantage of this analysis compared with previous analyses with other oral antidiabetes agents is the use of individual patient data as opposed to mean data.

2 | METHODS

2.1 | Patients and study designs

Study 1 (EMPA-REG MONO™) was a Phase III, double-blind, active- and placebo-controlled trial. Drug-naive patients with type 2 diabetes (no oral or injected antidiabetes medication for ≥12 weeks prior to randomization), aged ≥18 years, with body mass index (BMI) ≤45 kg/m² and HbA1c ≥7% to ≤10%, were randomized to receive empagliflozin 10 mg/d, empagliflozin 25 mg/d, sitagliptin 100 mg/d or placebo for 24 weeks. The primary end-point was change from baseline in HbA1c at week 24.12

Study 2 (EMPA-REG H2H-SU™) was a Phase III, double-blind, active-controlled trial. Metformin (immediate release, IR)-treated patients with type 2 diabetes, aged ≥18 years, with BMI ≤45 kg/m² and HbA1c ≥7% to ≤10% were randomized to receive empagliflozin 25 mg/d or glimepiride 1-4 mg/d as add-on to metformin for 104 weeks. Patients were required to be on an unchanged dose of metformin IR (≥1500 mg/d, maximum tolerated dose or maximum dose according to the local label) for ≥12 weeks prior to randomization. Glimepiride was initiated at a dose of 1 mg/d, with a recommendation for uptitration if fasting plasma glucose was >6.1 mmol/L to 2 mg/d at week 4, 3 mg/d at week 8 and 4 mg/d at week 12. The mean ± SD maximum titrated glimepiride dose was 2.71 ± 1.24 mg/d. The primary end-point was change from baseline in HbA1c at week 52 and week 104.16

2.2 | Statistical analyses

To compare the decline in HbA1c with empagliflozin 10 mg and 25 mg vs sitagliptin after 24 weeks (Study 1) and with empagliflozin 25 mg vs glimepiride after 52 weeks and 104 weeks (Study 2), the least squares (LS) mean change from baseline in HbA1c in each study was analysed using a mixed model for repeated measurements (MMRMs). The model included the fixed categorical effects of treatment, visit and treatment-by-visit interaction, as well as the continuous, fixed covariates of baseline, baseline-by-treatment, baseline-by-visit interaction and baseline-by-treatment-by-visit interaction. An unstructured covariance model was used to model the within-patient measurements. This model allowed estimation of the treatment-specific slope (ie, the magnitude of change in HbA1c for a unit change in baseline HbA1c) and its 95% confidence interval (CI) for the regression of change from baseline in HbA1c on the baseline HbA1c. P-values for the test of a difference of the slopes between treatment groups were calculated. Regression lines from scatter plots were estimated from a simple linear model within each treatment group, for which the change from baseline at the week of interest was calculated as the intercept + baseline HbA1c × slope. Thus, the difference between the slopes and the regression lines in the scatter plots was analysed using different models; slope values from both approaches are reported. Analyses were conducted in all patients who received ≥1 dose of study medication and who had a baseline HbA1c measurement. HbA1c values are presented as %. The following formula can be used to convert values to mmol/mol: [HbA1c (%) - 2.15] × 10.929.

3 | RESULTS

3.1 | Study 1

Baseline patient characteristics were similar between the empagliflozin and sitagliptin groups (Table 1). LS mean reductions
DEFRONZO ET AL.

in HbA1c at week 24 by baseline HbA1c are shown in Figure 1. A steeper slope of HbA1c reduction was observed with empagliflozin 10 mg or 25 mg compared with sitagliptin. The regression analysis showed slopes of \(-0.59\) (95% CI: \(-0.70, -0.47\)), \(-0.49\) (95% CI: \(-0.62, -0.37\)) and \(-0.29\) (95% CI: \(-0.42, -0.14\)) for empagliflozin 10 mg, empagliflozin 25 mg and sitagliptin, respectively. The slope was significantly different for both empagliflozin 10 mg (\(P < .001\)) and empagliflozin 25 mg (\(P = .023\)) compared with sitagliptin. There was no significant difference between the slopes for empagliflozin 10 mg vs empagliflozin 25 mg. Scatter plots of change from baseline in HbA1c at week 24 by baseline HbA1c are shown in Figure S1. The conclusions from slopes derived from regression lines of the scatter plots were similar to those from the LS means slope analyses (Figure S1).

3.2 | Study 2

Baseline patient characteristics were similar between the empagliflozin and glimepiride groups (Table 1). LS mean reductions in HbA1c at week 52 and week 104 by baseline HbA1c are shown in Figure 2. Steeper slopes of HbA1c reduction were observed with empagliflozin 25 mg than with glimepiride. The regression analysis showed slopes of \(-0.52\) (95% CI: \(-0.59, -0.44\)) and \(-0.32\) (95% CI: \(-0.39, -0.25\)) for empagliflozin 25 mg and glimepiride, respectively, at week 52 and \(-0.48\) (95% CI: \(-0.56, -0.40\)) and \(-0.37\) (95% CI: \(-0.45, -0.28\)) for empagliflozin 25 mg and glimepiride, respectively, at week 104. The slopes were steeper for empagliflozin 25 mg compared with glimepiride, reaching significance at week 52 (\(P < .001\)), and were of borderline significance at week 104 (\(P = .07\)). The slopes relating to the reduction in HbA1c as a function of time for empagliflozin-treated patients in this study were very similar to the slope for empagliflozin 25 mg in Study 1. Scatter plots of change from baseline in HbA1c at weeks 52 and 104 by baseline HbA1c are shown in Figure S2. The conclusions from slopes derived from regression lines of the scatter plots were similar to those from the LS means slope analyses (Figure S2).

4 | DISCUSSION

We analysed the effect of baseline HbA1c on the slope of HbA1c reduction with empagliflozin compared with two other commonly used antidiabetes agents (sitagliptin and glimepiride) using individual patient data from two randomized controlled trials.\(^\text{12,16}\) Our findings demonstrate that the decrement in HbA1c by baseline HbA1c, as reflected by the slope of HbA1c reduction, was greater with empagliflozin compared to both sitagliptin and glimepiride in patients with type 2 diabetes. The similar slopes of regression in HbA1c with empagliflozin 25 mg in Studies 1 and 2 emphasize the reproducibility of the empagliflozin results. Based on the results of Study 1, it can be predicted that for a starting HbA1c of 10.0%, 9.0% and 8.0%,
the decline in HbA1c after 24 weeks is −1.85%, −1.36% and −0.87%, respectively, with empagliflozin 25 mg and −1.28%, −1.00% and −0.71%, respectively, with sitagliptin. Based on the results of Study 2, it can be predicted that for a starting HbA1c of 10.0%, 9.0%, and 8.0%, the decline in HbA1c after 52 weeks is −1.85%, −1.33% and −0.82%, respectively, with empagliflozin 25 mg and −1.35%, −1.03% and −0.71%, respectively, with glimepiride. In Study 2, the difference between the slopes for empagliflozin and glimepiride narrowed slightly and nonsignificantly at 104 weeks vs 52 weeks. Although this could reflect a waning of the effect of empagliflozin, we believe that this most likely represents a chance observation. Most importantly, this difference did not approach statistical significance. It also is possible that the small nonsignificant difference in the slope could be explained by the fact that urinary glucose excretion would be expected to decrease as the HbA1c declined in the empagliflozin group. However, the reduction in HbA1c was near maximal at 12 weeks and did not change thereafter.

The observation of greater reductions in HbA1c with increasing baseline HbA1c is consistent with the mechanism of action of SGLT2 inhibitors, which act by reducing the renal threshold for glucose spillage into the urine to values less than the normal fasting plasma glucose concentration. SGLT2 inhibitors target glucose that would otherwise be reabsorbed by the kidney. Thus, it is expected that the higher the glucose concentration up till the
(untreated) renal threshold for glucose, the greater the incremental excretion of glucose into the urine with SGLT2 inhibition, and, ultimately, the greater the expected decline in HbA1c. It should be noted that the reduction in HbA1c observed with SGLT2 inhibitors is approximately 50% of that expected based on urinary glucose excretion, likely because of an increase in endogenous glucose production and increased glucose reabsorption by SGLT1, which is capable of reabsorbing up to 30%-40% of the filtered glucose load. If the increase in endogenous glucose production were to be prevented or if glucose reabsorption by SGLT1 were blocked, the decline in HbA1c for any given starting HbA1c would potentially be even greater with empagliflozin compared to sitagliptin or glimepiride. Further, the slope of HbA1c reduction in other commonly used antidiabetes agents will be influenced by their mechanism of action, that is, increased insulin secretion, glucagon suppression, inhibition of endogenous glucose production or insulin sensitization, which impose physiological limits to their efficacy. SGLT2 inhibitors reduce the renal threshold for glucose to well below the fasting plasma glucose concentration observed in individuals with normal glucose tolerance. This may contribute to a disproportionately greater HbA1c reduction with SGLT2 inhibitors than with other antidiabetes agents with increasing plasma glucose levels as long as GFR is not significantly reduced. Glycosuria with empagliflozin decreases with decreasing estimated GFR, and, in patients with type 2 diabetes who have a reduced GFR, the glucose-lowering effect of empagliflozin is reduced.

These are some limitations to the present analyses. First, these were post-hoc analyses. Second, these exploratory analyses did not include the placebo arm of Study 1; this is different from the approach of the primary analysis of the study that included placebo as the main comparator. In conclusion, reductions in HbA1c with increasing baseline HbA1c are greater with empagliflozin compared with sitagliptin or glimepiride in patients with type 2 diabetes.

ACKNOWLEDGEMENTS

Medical writing assistance, supported financially by Boehringer Ingelheim, was provided by Elizabeth Ng of FleishmanHillard Fishburn, London, the United Kingdom, during the preparation of this article. The authors were fully responsible for all content and editorial decisions, were involved at all stages of manuscript development and have approved the final version. Some of the data included in this manuscript were presented in abstract form at the 75th Scientific Sessions of the American Diabetes Association, Boston, Massachusetts, 5-9 June 2015.

CONFLICT OF INTERESTS

The studies included in these analyses were funded by the Boehringer Ingelheim & Eli Lilly and Company Diabetes Alliance. RAD discloses membership of Advisory Boards (Astra Zeneca, Novo Nordisk, Janssen, Boehringer-Ingelheim, Intarcia, Elcelyx), research support (Boehringer-Ingelheim, Takeda, Astra Zeneca, Janssen) and speaker’s bureau (Novo-Nordisk, Astra Zeneca). EF discloses membership of Scientific Advisory Boards (Boehringer Ingelheim/Eli Lilly and Company, Merck Sharp & Dohme, Sanofi), ad hoc consulting (Janssen, AstraZeneca), occasional speaking engagements (AstraZeneca, Takeda, Novo Nordisk, Sanofi, Mitsubishi, Eli Lilly and Company, Boehringer Ingelheim, Merck Sharp & Dohme) and research grant support (Eli Lilly and Company and Boehringer Ingelheim). GS discloses membership of Advisory Boards (Eli Lilly, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Takeda and Johnson & Johnson) and is a speaker for Eli Lilly, Boehringer Ingelheim, Takeda, AstraZeneca, Bristol-Myers Squibb, Sanofi, Merck and Novo Nordisk. SH, UE, CL and SSL are employees of Boehringer Ingelheim. TH was an employee of Boehringer Ingelheim at the time these analyses were conducted. SSL owns shares in Novo Nordisk A/S and shares in dynamically traded investment funds which may own stocks from pharmaceutical companies.

AUTHOR CONTRIBUTIONS

RAD, EF, GS, SH, UE, CL, TH and SSL contributed to the interpretation of data and to the drafting of the manuscript and have approved the final version. All authors had full access to the study data and were responsible for the final decision to submit the manuscript.

ORCID

Ralph A. DeFronzo http://orcid.org/0000-0003-3839-1724
Ele Ferrannini http://orcid.org/0000-0002-1384-1584

REFERENCES

1. Sherifali D, Nerenberg K, Pullenayegum E, Cheng JE, Gerstein HC. The effect of oral antidiabetic agents on A1C levels: a systematic review and meta-analysis. Diabetes Care. 2010;33:1859-1864.
2. Esposito K, Chiodini P, Capuano A, Maiorino MI, Bellastella G, Giugliano D. Baseline glycemic parameters predict the hemoglobin A1c response to DPP-4 inhibitors: meta-regression analysis of 78 randomized controlled trials with 20,053 patients. Endocrine. 2014;46:43-51.
3. Esposito K, Chiodini P, Bellastella G, Maiorino MI, Giugliano D. Proportion of patients at HbA1c target <7% with eight classes of antidiabetic drugs in type 2 diabetes: systematic review of 218 randomized controlled trials with 78 945 patients. Diabetes Obes Metab. 2012;14:228-233.
4. Ahrén B, Mathieu C, Bader G, Schweizer A, Foley JE. Efficacy of vildagliptin versus sulfonylureas as add-on therapy to metformin: comparison of results from randomised controlled and observational studies. Diabetologia. 2014;57:1304-1307.
5. Ahrén B, Foley JE, Pacini G, Schweizer A. Improved meal-related β-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. Diabetes Care. 2005;28:1936-1940.
6. Wajchenberg BL. Beta-cell failure in diabetes and preservation by clinical treatment. Endocr Rev. 2007;28:187-218.
7. Abdul-Ghani M, DeFronzo R, Norton L. Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30-50% of filtered glucose load in humans. Diabetes. 2013;62:3324-3328.
8. DeFronzo RA, Davidson JA, del Prato S. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes Obes Metab. 2012;14:5-14.
9. DeFronzo RA, Hompesch M, Kaschayanula S, et al. Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes. Diabetes Care. 2013;36:3169-3176.
10. Ferrannini E, Solini A. SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. Nat Rev Endocrinol. 2012;8:495-502.
11. Grempler R, Thomas L, Eckhardt M, et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterization and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab. 2012;14:83-90.
12. Roden M, Weng J, Elbracht J, et al. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2013;1:208-219.
13. Häring H-U, Merker L, Seewaldt-Becker E, et al. Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week randomized, double-blind, placebo-controlled trial. Diabetes Care. 2013;36:3396-3404.
14. Häring H-U, Merker L, Seewaldt-Becker E, et al. Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care. 2014;37:1650-1659.
15. Kovacs CS, Seshiah V, Swallow R, et al. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. Diabetes Obes Metab. 2013;16:147-158.
16. Ridderstråle M, Andersen KR, Zeller C, et al. Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial. Lancet Diabetes Endocrinol. 2014;2:691-700.
17. Merovci A, Solis-Herrera C, Daniele G, et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest. 2014;124:509-514.
18. Macha S, Matteus M, Halabi A, Pinnetti S, Woerle HJ, Broedl UC. Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment. Diabetes Obes Metab. 2014;16:215-222.
19. Barnett AH, Mithal A, Manassie J, et al. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2014;2:369-384.

SUPPORTING INFORMATION
Additional Supporting Information may be found online in the supporting information tab for this article.

How to cite this article: DeFronzo RA, Ferrannini E, Schernthaner G, et al. Slope of change in HbA1c from baseline with empagliflozin compared with sitagliptin or glimepiride in patients with type 2 diabetes. Endocrinol Diab Metab. 2018;1:e16. https://doi.org/10.1002/edm2.16